Xaira Therapeutics
An integrated biotechnology company utilising artificial intelligence (AI) to rethink the drug discovery and development process.
Founded and jointly incubated by ARCH Venture Partners and Foresite Labs, and co-founded by Dr. David Baker of the UW Medicine Institute for Protein Design, Xaira launched in May 2024 with more than $1 billion in committed capital in support of its mission.
Xaira’s internal platforms incorporate leading technologies and personnel which were spun out into Xaira at inception from Illumina’s long-standing functional genomics R&D effort. The company has also integrated a leading proteomics group from Interline Therapeutics.
Latest Xaira Therapeutics News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze